EA201491575A1 - Антитела к матриксной металлопротеиназе 9 - Google Patents

Антитела к матриксной металлопротеиназе 9

Info

Publication number
EA201491575A1
EA201491575A1 EA201491575A EA201491575A EA201491575A1 EA 201491575 A1 EA201491575 A1 EA 201491575A1 EA 201491575 A EA201491575 A EA 201491575A EA 201491575 A EA201491575 A EA 201491575A EA 201491575 A1 EA201491575 A1 EA 201491575A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
matrix metalloproteinase
mmp
functional fragment
binding proteins
Prior art date
Application number
EA201491575A
Other languages
English (en)
Inventor
Виктория СМИТ
Скотт Макколи
Original Assignee
Джилид Байолоджикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Байолоджикс, Инк. filed Critical Джилид Байолоджикс, Инк.
Publication of EA201491575A1 publication Critical patent/EA201491575A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Abstract

Согласно настоящему изобретению предложены композиции и способы их применения, включающие связывающие белки, например антитела и их антигенсвязывающие фрагменты, которые связываются с белком матриксной металлопротеиназы-9 (ММП-9) (ММП-9 также известна как желатиназа-В), в частности такие, в которых связывающие белки содержат тяжелую цепь иммуноглобулина (Ig) (или ее функциональный фрагмент) и легкую цепь Ig (или ее функциональный фрагмент).
EA201491575A 2012-02-29 2012-02-29 Антитела к матриксной металлопротеиназе 9 EA201491575A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/027160 WO2013130078A1 (en) 2012-02-29 2012-02-29 Antibodies to matrix metalloproteinase 9

Publications (1)

Publication Number Publication Date
EA201491575A1 true EA201491575A1 (ru) 2015-01-30

Family

ID=45816000

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491575A EA201491575A1 (ru) 2012-02-29 2012-02-29 Антитела к матриксной металлопротеиназе 9

Country Status (23)

Country Link
US (4) US9550836B2 (ru)
EP (1) EP2820048B1 (ru)
JP (1) JP6067756B2 (ru)
KR (1) KR20140130724A (ru)
CN (1) CN104395345A (ru)
AP (1) AP2014007907A0 (ru)
AU (4) AU2012318302C1 (ru)
BR (1) BR112014021477A2 (ru)
CA (1) CA2865530C (ru)
CL (1) CL2014002282A1 (ru)
CO (1) CO7061040A2 (ru)
CR (1) CR20140443A (ru)
EA (1) EA201491575A1 (ru)
EC (1) ECSP14020504A (ru)
ES (1) ES2731441T3 (ru)
HK (2) HK1205153A1 (ru)
IN (1) IN2014DN08011A (ru)
MD (1) MD20140107A2 (ru)
MX (1) MX2014010449A (ru)
PH (1) PH12014501931A1 (ru)
SG (1) SG11201405305PA (ru)
WO (1) WO2013130078A1 (ru)
ZA (1) ZA201406319B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20131376A1 (es) 2010-08-27 2013-11-25 Gilead Biologics Inc Anticuerpos para metaloproteinasa-9 de matriz
US9550836B2 (en) 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies
SG10201610788VA (en) * 2012-02-29 2017-03-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
TW201544511A (zh) * 2014-02-27 2015-12-01 Gilead Sciences Inc 針對基質金屬蛋白酶９之抗體及其使用方法
EP2985296A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP2985295A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
CN105037553B (zh) * 2015-08-20 2018-04-17 内蒙古蒙元生物基因科技有限公司 一种能够检测癌症的免疫球蛋白
WO2017177179A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
US10326830B1 (en) * 2016-09-02 2019-06-18 Amazon Technologies, Inc. Multipath tunneling to a service offered at several datacenters
EP3555138A1 (en) 2016-12-16 2019-10-23 Université de Bordeaux Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
WO2018170488A1 (en) * 2017-03-17 2018-09-20 Gilead Sciences, Inc. Method of purifying an antibody
CN111051339A (zh) 2017-07-18 2020-04-21 第一三共株式会社 活性mmp-9-结合肽
CN110885375B (zh) * 2019-12-20 2021-07-02 南京融捷康生物科技有限公司 特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用
CN111785321B (zh) * 2020-06-12 2022-04-05 浙江工业大学 一种基于深度卷积神经网络的dna绑定残基预测方法
CN117327186B (zh) * 2023-07-12 2024-03-12 北京达成生物科技有限公司 结合mmp3蛋白的双特异性抗体及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
EP1203025B1 (en) * 1999-07-13 2009-07-01 University Of Southern California Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and beta1 integrins
CN1459505A (zh) * 2002-05-21 2003-12-03 赵平 中国汉族人基质金属蛋白酶－9基因重构、表达、纯化及其医学应用
EP1545611B1 (en) * 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
ES2388932T3 (es) * 2005-12-02 2012-10-19 Genentech, Inc. Polipéptidos de unión y usos de los mismos
TW200911835A (en) * 2007-06-08 2009-03-16 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
US8013125B2 (en) * 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
WO2009111450A2 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 binding proteins
JP2013533206A (ja) * 2008-10-22 2013-08-22 ダイアクス コーポレーション 炎症性障害のための、プロテアーゼ結合タンパク質を含む併用療法
US20110286916A1 (en) * 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
US8697078B2 (en) * 2010-01-27 2014-04-15 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
PE20131376A1 (es) 2010-08-27 2013-11-25 Gilead Biologics Inc Anticuerpos para metaloproteinasa-9 de matriz
US9550836B2 (en) 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies
SG10201610788VA (en) 2012-02-29 2017-03-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9

Also Published As

Publication number Publication date
HK1205153A1 (en) 2015-12-11
KR20140130724A (ko) 2014-11-11
CO7061040A2 (es) 2014-09-19
MX2014010449A (es) 2015-02-10
IN2014DN08011A (ru) 2015-05-01
ES2731441T3 (es) 2019-11-15
US11634505B2 (en) 2023-04-25
ZA201406319B (en) 2016-02-24
AU2017216508A1 (en) 2017-08-31
CR20140443A (es) 2014-11-17
BR112014021477A2 (pt) 2018-06-12
AU2012318302A1 (en) 2013-09-19
US20190127486A1 (en) 2019-05-02
CN104395345A (zh) 2015-03-04
PH12014501931A1 (en) 2014-11-24
AU2015242967A1 (en) 2015-11-05
US20210054101A1 (en) 2021-02-25
US20170183421A1 (en) 2017-06-29
HK1208036A1 (en) 2016-02-19
CA2865530C (en) 2019-02-19
AU2017261626A1 (en) 2017-12-07
AU2017216508B2 (en) 2019-03-07
US10800857B2 (en) 2020-10-13
MD20140107A2 (ru) 2015-03-31
AU2015242967B2 (en) 2017-08-24
SG11201405305PA (en) 2014-09-26
AP2014007907A0 (en) 2014-08-31
JP2015514394A (ja) 2015-05-21
ECSP14020504A (es) 2015-09-30
CL2014002282A1 (es) 2015-02-20
US9550836B2 (en) 2017-01-24
NZ629888A (en) 2017-02-24
EP2820048B1 (en) 2019-04-17
EP2820048A1 (en) 2015-01-07
CA2865530A1 (en) 2013-09-06
US20150140580A1 (en) 2015-05-21
AU2012318302C1 (en) 2017-06-15
JP6067756B2 (ja) 2017-01-25
WO2013130078A1 (en) 2013-09-06
AU2012318302B2 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
EA201591153A1 (ru) Антитела, связывающиеся с tl1a, и их применение
PE20150023A1 (es) Proteinas de union a antigeno st2
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
EA201490677A1 (ru) Связывающие антиген cd27l белки
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
EA201291065A1 (ru) Антитела против vla-4
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
EA201590918A1 (ru) Антитела к bmp-6
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
EA202191187A1 (ru) Антитела к ctla4, фрагменты антител, их иммуноконъюгаты и их применение
TH148296B (th) แอนติบอดีต้านเมทริกซ์เมทัลโลโปรตีเนส 9 (Antibodies to matrix metalloproteinase 9)